Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical Limited has announced its Annual General Meeting for shareholders on November 14, 2024, with a deadline for director nominations set for October 2, 2024. The biotech company is actively developing Xanamem, a promising new treatment for Alzheimer’s, depression, and potentially other neurological disorders, and has shared positive results from recent clinical trials.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
